医学
围手术期
化疗
肿瘤科
肺癌
内科学
病态的
新辅助治疗
肺
外科
临床试验
顺铂
完全响应
细胞
临床研究阶段
癌症
负效应
循环肿瘤细胞
循环肿瘤DNA
作者
Xiaoliang Zhao,Bin Zhang,Chenguang Li,Lianmin Zhang,Meng Wang,Ziqiang Tian,Shengguang Wang,Qiang Zhang,Huilai Lv,Chong Pang,Shiwang Wen,Xiaofei Wang,Wei Wei,Yu Zhang,Huang Wuhao,Jianquan Zhu,Yue Li,Chen Chen,Yao Tang,Bin Jia
标识
DOI:10.1038/s41591-026-04745-4
摘要
Resectable non-small cell lung cancer (NSCLC) carries a high risk of postoperative recurrence, underscoring the need for effective perioperative therapies. This nonrandomized, noncomparative phase 2 trial evaluated neoadjuvant ivonescimab monotherapy (cohort 1) or in combination with chemotherapy (cohort 2), followed by surgery and adjuvant ivonescimab. In cohort 2, the major pathological response (MPR) rate was 70.1% (47/67; 95% confidence interval (CI) = 57.7-80.7); the lower bound of the 80% two-sided CI exceeded the historical control rate of 41% and the primary endpoint was met. The MPR rate in cohort 1 was 60.0% (6/10; 95% CI = 26.2-87.8). Among patients who achieved MPR, 83.3% (5/6) in cohort 1 and 97.9% (46/47) in cohort 2 had residual viable tumor (RVT) of ≤5%, respectively. Grade 3 or higher treatment-related adverse events (AEs) occurred in 36.4% (4/11) patients in cohort 1 and 30.4% (24/79) of those in cohort 2, with no grade 3 or higher hemorrhage or treatment-related death. Treatment-related surgery delay occurred in one (1.3%) patient. Surgery-related AEs related to ivonescimab occurred in 10.0% (1/10) and 10.4% (7/67) patients in the two cohorts, respectively, with no grade 3 or higher events reported. These data support perioperative ivonescimab with or without chemotherapy as a promising strategy for resectable NSCLC. ClinicalTrials.gov identifier: NCT05247684 .
科研通智能强力驱动
Strongly Powered by AbleSci AI